For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Keyword

Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...

Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy

Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )

Advances in lung cancer and current situation in Romania

Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara, On...

Advances in lung cancer and current situation in Romania ( Dr Serban Negru - University of Medicine and Pharmacy Victor Babes Timisoara, OncoHelp Cancer Center )

ALCSI: Raising lung cancer screening awareness in the US

Priyanka Senthil - American Lung Cancer Screening Initiative

ALCSI: Raising lung cancer screening awareness in the US ( Priyanka Senthil - American Lung Cancer Screening Initiative )

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...

Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

Dr Christina Baik - University of Washington School of Medicine, Seattle, USA

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy...

Prof Heather Wakelee - Stanford University, Stanford, USA

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival o...

Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

More from ecancer